Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a progressive interstitial lung disease marked by scarring of lung tissue, declining respiratory function, and poor prognosis if left untreated. The condition primarily affects older adults, with its cause still not fully understood, though genetic, environmental, and immune factors appear to play contributory roles. Diagnosis has become more precise through the use of high-resolution CT imaging and multidisciplinary evaluation, enabling differentiation from other fibrotic lung diseases. The therapeutic landscape has advanced with the introduction of antifibrotic agents such as pirfenidone and nintedanib, which slow disease progression and improve survival outcomes. Supportive strategies, including pulmonary rehabilitation, oxygen therapy, and vaccination, further contribute to maintaining quality of life. Clinical management also involves timely evaluation for lung transplantation in eligible patients, providing the only curative option. Beyond pharmacologic approaches, research is exploring novel antifibrotic agents, immune modulators, and regenerative therapies, including stem-cell–based strategies aimed at reversing or halting fibrosis. The unpredictable nature of disease progression requires close monitoring with pulmonary function testing, imaging, and biomarkers to guide decisions. Patient education, psychological support, and palliative care are integral components of comprehensive management. Idiopathic pulmonary fibrosis illustrates the ongoing need for innovation, as current therapies primarily slow but do not reverse disease. Continued exploration of molecular pathways and targeted interventions offers hope for a future in which this devastating disease becomes more manageable and potentially curable.